marked.bio

WRN helicase inhibitor · small molecule

HRO761

1 active trials, targeting WRN. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
MSI-H / dMMR 1 1 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of HRO761.

  1. Novartis 1

Trials

1 of 1 trials shown

  1. Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

    Active, not recruiting Phase 1 Novartis Started 2023Primary completion 2027-08 NCT05838768

    HRO761pembrolizumab FDA EUirinotecan

    Patients with advanced unresectable or metastatic MSIhi or MMR deficient (dMMR) solid tumors who have progressed after or are intolerant to prior standard therapy…

    MSI-H / dMMRMSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers